company background image
4130

Genovate Biotechnology TPEX:4130 Stock Report

Last Price

NT$23.85

Market Cap

NT$2.6b

7D

-2.5%

1Y

-1.1%

Updated

16 May, 2022

Data

Company Financials
4130 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

4130 Stock Overview

Genovate Biotechnology Co., Ltd. operates as a specialty pharmaceutical company in Taiwan.

Genovate Biotechnology Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Genovate Biotechnology
Historical stock prices
Current Share PriceNT$23.85
52 Week HighNT$32.85
52 Week LowNT$21.05
Beta0.10
1 Month Change-5.36%
3 Month Change-4.22%
1 Year Change-1.11%
3 Year Change-6.28%
5 Year Change-30.52%
Change since IPO24.07%

Recent News & Updates

Shareholder Returns

4130TW PharmaceuticalsTW Market
7D-2.5%-4.6%-3.4%
1Y-1.1%3.0%0.7%

Return vs Industry: 4130 underperformed the TW Pharmaceuticals industry which returned 3% over the past year.

Return vs Market: 4130 underperformed the TW Market which returned 0.7% over the past year.

Price Volatility

Is 4130's price volatile compared to industry and market?
4130 volatility
4130 Average Weekly Movement6.2%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement4.6%
10% most volatile stocks in TW Market8.3%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 4130 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 4130's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995181n/ahttps://www.genovate-bio.com

Genovate Biotechnology Co., Ltd. operates as a specialty pharmaceutical company in Taiwan. The company offers central nervous system drugs, cardiovascular drugs, musculoskeletal drugs, immune preparation drugs, anti-infective agents, anticancer drugs, anti-viral drugs, respiratory drugs, genitourinary drugs, and gastrointestinal drugs. Genovate Biotechnology Co., Ltd.

Genovate Biotechnology Fundamentals Summary

How do Genovate Biotechnology's earnings and revenue compare to its market cap?
4130 fundamental statistics
Market CapNT$2.56b
Earnings (TTM)-NT$17.67m
Revenue (TTM)NT$430.37m

5.9x

P/S Ratio

-144.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4130 income statement (TTM)
RevenueNT$430.37m
Cost of RevenueNT$287.68m
Gross ProfitNT$142.69m
Other ExpensesNT$160.36m
Earnings-NT$17.67m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.16
Gross Margin33.16%
Net Profit Margin-4.11%
Debt/Equity Ratio0%

How did 4130 perform over the long term?

See historical performance and comparison

Dividends

1.5%

Current Dividend Yield

-212%

Payout Ratio

Valuation

Is Genovate Biotechnology undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


1.86x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: 4130 (NT$23.85) is trading above our estimate of fair value (NT$6.98)

Significantly Below Fair Value: 4130 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 4130 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.

PE vs Market: 4130 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4130's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4130's PB Ratio (1.9x) is in line with the TW Pharmaceuticals industry average.


Future Growth

How is Genovate Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


50.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genovate Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Genovate Biotechnology performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-42.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 4130 is currently unprofitable.

Growing Profit Margin: 4130 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4130 is unprofitable, and losses have increased over the past 5 years at a rate of 42.5% per year.

Accelerating Growth: Unable to compare 4130's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4130 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).


Return on Equity

High ROE: 4130 has a negative Return on Equity (-1.28%), as it is currently unprofitable.


Financial Health

How is Genovate Biotechnology's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 4130's short term assets (NT$741.0M) exceed its short term liabilities (NT$161.3M).

Long Term Liabilities: 4130's short term assets (NT$741.0M) exceed its long term liabilities (NT$18.9M).


Debt to Equity History and Analysis

Debt Level: 4130 is debt free.

Reducing Debt: 4130 has no debt compared to 5 years ago when its debt to equity ratio was 12.8%.

Debt Coverage: 4130 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 4130 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Genovate Biotechnology current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


1.47%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 4130's dividend (1.47%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (2.4%).

High Dividend: 4130's dividend (1.47%) is low compared to the top 25% of dividend payers in the TW market (6.16%).


Stability and Growth of Payments

Stable Dividend: 4130 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 4130's dividend payments have increased, but the company has only paid a dividend for 9 years.


Earnings Payout to Shareholders

Earnings Coverage: 4130 is paying a dividend but the company is unprofitable.


Cash Payout to Shareholders

Cash Flow Coverage: 4130 is paying a dividend but the company has no free cash flows.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

15.8yrs

Average board tenure


CEO

Genovate Biotechnology has no CEO, or we have no data on them.


Board Members

Experienced Board: 4130's board of directors are seasoned and experienced ( 15.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Genovate Biotechnology Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Genovate Biotechnology Co., Ltd.
  • Ticker: 4130
  • Exchange: TPEX
  • Founded: 1995
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: NT$2.558b
  • Shares outstanding: 107.25m
  • Website: https://www.genovate-bio.com

Number of Employees


Location

  • Genovate Biotechnology Co., Ltd.
  • No. 1, Gongye 1st Road
  • Hsinchu Industrial Park
  • Hsinchu City
  • 30351
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/16 00:00
End of Day Share Price2022/05/13 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.